SERPASIL-ESIDRIX #2
LOE ApproachingNDAORALTABLET
Approved
May 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERPASIL-ESIDRIX #2 is an oral tablet combination product approved in 1959 by Novartis. The specific indications and mechanism of action are not documented in available data, limiting clinical context for career evaluation.
LOE Approaching
Product approaching loss of exclusivity with minimal linked job openings, indicating significant contraction of the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring on this brand. Career opportunities are limited to retention roles in a contracting portfolio product.
Brand ManagerField Sales Representative
Worked on SERPASIL-ESIDRIX #2 at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.